AU2023265064A1 - Salt and crystal forms of an epidermal growth factor receptor inhibitor - Google Patents

Salt and crystal forms of an epidermal growth factor receptor inhibitor Download PDF

Info

Publication number
AU2023265064A1
AU2023265064A1 AU2023265064A AU2023265064A AU2023265064A1 AU 2023265064 A1 AU2023265064 A1 AU 2023265064A1 AU 2023265064 A AU2023265064 A AU 2023265064A AU 2023265064 A AU2023265064 A AU 2023265064A AU 2023265064 A1 AU2023265064 A1 AU 2023265064A1
Authority
AU
Australia
Prior art keywords
egfr
mesylate salt
ray powder
powder diffraction
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023265064A
Other languages
English (en)
Inventor
Eric GRUFF
Shanming KUANG
Anjali Pandey
Harsh Shah
Tian XIE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blueprint Medicines Corp
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of AU2023265064A1 publication Critical patent/AU2023265064A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2023265064A 2022-05-04 2023-05-04 Salt and crystal forms of an epidermal growth factor receptor inhibitor Pending AU2023265064A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263338371P 2022-05-04 2022-05-04
US63/338,371 2022-05-04
PCT/US2023/020925 WO2023215431A1 (en) 2022-05-04 2023-05-04 Salt and crystal forms of an epidermal growth factor receptor inhibitor

Publications (1)

Publication Number Publication Date
AU2023265064A1 true AU2023265064A1 (en) 2024-11-14

Family

ID=86688767

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023265064A Pending AU2023265064A1 (en) 2022-05-04 2023-05-04 Salt and crystal forms of an epidermal growth factor receptor inhibitor

Country Status (12)

Country Link
US (1) US20250282761A1 (cg-RX-API-DMAC7.html)
EP (1) EP4519254A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025517634A (cg-RX-API-DMAC7.html)
KR (1) KR20250012078A (cg-RX-API-DMAC7.html)
CN (1) CN119923392A (cg-RX-API-DMAC7.html)
AU (1) AU2023265064A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251624A1 (cg-RX-API-DMAC7.html)
IL (1) IL316663A (cg-RX-API-DMAC7.html)
MX (1) MX2024013485A (cg-RX-API-DMAC7.html)
TW (1) TW202409016A (cg-RX-API-DMAC7.html)
UY (1) UY40256A (cg-RX-API-DMAC7.html)
WO (1) WO2023215431A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202432143A (zh) * 2022-11-01 2024-08-16 美商纜圖藥品公司 用於治療癌症之egfr抑制劑

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493419A (zh) * 2020-03-18 2021-10-12 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
CN113493420B (zh) * 2020-03-18 2025-04-25 南京迈晟科技有限责任公司 Egfr酪氨酸激酶抑制剂及其用途
EP4237418B1 (en) * 2020-10-30 2026-02-11 Blueprint Medicines Corporation Pyrimidine compounds, compositions, and medicinal applications thereof
EP4237088A1 (en) * 2020-10-30 2023-09-06 Blueprint Medicines Corporation Pyrimidine compounds, compositions, and medicinal applications thereof

Also Published As

Publication number Publication date
UY40256A (es) 2023-11-15
JP2025517634A (ja) 2025-06-10
TW202409016A (zh) 2024-03-01
EP4519254A1 (en) 2025-03-12
MX2024013485A (es) 2024-12-06
KR20250012078A (ko) 2025-01-23
WO2023215431A1 (en) 2023-11-09
US20250282761A1 (en) 2025-09-11
CN119923392A (zh) 2025-05-02
IL316663A (en) 2024-12-01
CA3251624A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
US20240239735A1 (en) Acid addition salt of rock inhibitor, and crystal form, composition and pharmaceutical use thereof
US10723730B2 (en) Solid forms of a selective CDK4/6 inhibitor
US9630952B2 (en) Crystalline forms of afatinib di-maleate
WO2021073498A1 (zh) Egfr抑制剂、组合物及其制备方法
US9879008B2 (en) 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, preparation method therefor and medicinal use thereof
CN111499634B (zh) 一种喹唑啉化合物及其在医药上的应用
CN115461341A (zh) 2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)-1h-吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁烷-3-基)哌嗪-1-基]戊-2-烯腈的晶型
CN114867531B (zh) Egfr抑制剂
EP3770164A1 (en) Crystalline forms of lorlatinib maleate
US10640487B2 (en) Solid state forms of Nilotinib salts
CN112424187B (zh) 抑制jak的化合物的昔萘酸盐
CN121889396A (zh) 用于治疗甲状腺眼病的林西替尼的结晶盐
US20250282761A1 (en) Salt and crystal forms of an epidermal growth factor receptor inhibitor
WO2022022398A1 (zh) 一种嘧啶类化合物的盐和晶型及其制备方法
US11878980B2 (en) Solid forms of TTK inhibitor
JP7712994B2 (ja) 疾患の治療用のホスホイノシチド3-キナーゼ(pi3k)のアロステリッククロメノン阻害剤
EP4353729A1 (en) Polymorph of imidazolidinone compound, preparation method therefor and use thereof
JP2025525475A (ja) N-[4-(4-[[2-(ジメチルアミノ)エチル]アミノ]-3-メチル-1H-ピラゾロ[3,4-d]ピリミジン-6-イル)-2-フルオロフェニル]-2,5-ジフルオロベンゼンスルホンアミドの塩及びそれらの結晶形態
WO2025247352A1 (zh) 化合物的晶型、盐型、溶剂合物、水合物及其用途
TW202342041A (zh) 一種藥物組合物及所含活性成分化合物的製備方法
HK1260821B (en) Crystals of aniline pyrimidine compound serving as egfr inhibitor